IL245281A0 - Methods and preparations for the treatment of cancer - Google Patents
Methods and preparations for the treatment of cancerInfo
- Publication number
- IL245281A0 IL245281A0 IL245281A IL24528116A IL245281A0 IL 245281 A0 IL245281 A0 IL 245281A0 IL 245281 A IL245281 A IL 245281A IL 24528116 A IL24528116 A IL 24528116A IL 245281 A0 IL245281 A0 IL 245281A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895308P | 2013-10-24 | 2013-10-24 | |
| PCT/US2014/061418 WO2015061229A1 (en) | 2013-10-24 | 2014-10-20 | Methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL245281A0 true IL245281A0 (en) | 2016-06-30 |
Family
ID=52993423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245281A IL245281A0 (en) | 2013-10-24 | 2016-04-21 | Methods and preparations for the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9511050B2 (enExample) |
| EP (1) | EP3060207A4 (enExample) |
| JP (1) | JP6389884B2 (enExample) |
| KR (1) | KR20160065986A (enExample) |
| CN (1) | CN105848654B (enExample) |
| AU (1) | AU2014340398A1 (enExample) |
| CA (1) | CA2927148A1 (enExample) |
| IL (1) | IL245281A0 (enExample) |
| MX (1) | MX2016004678A (enExample) |
| RU (1) | RU2016114498A (enExample) |
| WO (1) | WO2015061229A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8232310B2 (en) * | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物 |
| PL3372605T3 (pl) | 2008-10-22 | 2022-03-07 | Array Biopharma Inc. | Podstawione związki pirazolo[1,5-a]pirymidynowe jako inhibitory kinaz trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| HUE044025T2 (hu) | 2010-05-20 | 2019-09-30 | Array Biopharma Inc | Makrociklusos vegyületek mint TRK-kináz inhibitorok |
| JP6130491B2 (ja) | 2012-04-12 | 2017-05-17 | ジョージタウン・ユニバーシティGeorgetown University | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
| CA2927148A1 (en) * | 2013-10-24 | 2015-04-30 | Georgetown University | Methods and compositions for treating cancer |
| WO2016057698A1 (en) | 2014-10-09 | 2016-04-14 | Tokalas, Inc. | Indolinone compounds and uses thereof |
| PT3699181T (pt) | 2014-11-16 | 2023-04-05 | Array Biopharma Inc | Forma cristalina de hidrogenossulfato de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー, インコーポレイテッドLoxo Oncology, Inc. | Trk阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| US9822122B2 (en) | 2016-03-31 | 2017-11-21 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CU20180125A7 (es) | 2016-04-04 | 2019-05-03 | Loxo Oncology Inc | Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-alpirimidin-3-il)-3 hidroxipirrolidina-1-carboxamida |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| MX392604B (es) | 2016-05-18 | 2025-03-24 | Array Biopharma Inc | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo. |
| US10761081B2 (en) * | 2016-06-12 | 2020-09-01 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| US10613088B2 (en) * | 2016-06-12 | 2020-04-07 | Mohammad Abdolahad | Method and system for metastasis diagnosis and prognosis |
| CN109789127B (zh) | 2016-07-29 | 2022-03-25 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2018229294B2 (en) * | 2017-02-28 | 2024-06-13 | Exact Sciences Corporation | Detecting prostate cancer |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN110845389A (zh) * | 2019-10-17 | 2020-02-28 | 袁健 | 一种新型i型拓扑异构酶抑制剂 |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0133244B1 (en) | 1983-07-22 | 1990-12-05 | E.I. Du Pont De Nemours And Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| DE69922997T2 (de) | 1998-12-04 | 2005-12-15 | Neurosearch A/S | Verwendung von isatinderivaten als ionenkanalaktivierende mittel |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| EP3034510A1 (en) | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CA2711003C (en) * | 2006-12-29 | 2017-02-21 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
| DK2154966T3 (da) | 2007-04-20 | 2013-11-18 | Univ New York State Res Found | Benzimidazoler og farmaceutiske sammensætninger deraf |
| US20130259927A1 (en) | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
| JP6130491B2 (ja) | 2012-04-12 | 2017-05-17 | ジョージタウン・ユニバーシティGeorgetown University | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
| CA2927148A1 (en) * | 2013-10-24 | 2015-04-30 | Georgetown University | Methods and compositions for treating cancer |
-
2014
- 2014-10-20 CA CA2927148A patent/CA2927148A1/en not_active Abandoned
- 2014-10-20 CN CN201480071102.0A patent/CN105848654B/zh active Active
- 2014-10-20 WO PCT/US2014/061418 patent/WO2015061229A1/en not_active Ceased
- 2014-10-20 RU RU2016114498A patent/RU2016114498A/ru not_active Application Discontinuation
- 2014-10-20 KR KR1020167013692A patent/KR20160065986A/ko not_active Withdrawn
- 2014-10-20 JP JP2016526034A patent/JP6389884B2/ja active Active
- 2014-10-20 EP EP14855801.8A patent/EP3060207A4/en not_active Withdrawn
- 2014-10-20 US US15/030,713 patent/US9511050B2/en active Active
- 2014-10-20 MX MX2016004678A patent/MX2016004678A/es unknown
- 2014-10-20 AU AU2014340398A patent/AU2014340398A1/en not_active Abandoned
-
2016
- 2016-04-21 IL IL245281A patent/IL245281A0/en unknown
- 2016-11-30 US US15/365,794 patent/US20170157089A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160263086A1 (en) | 2016-09-15 |
| EP3060207A1 (en) | 2016-08-31 |
| AU2014340398A1 (en) | 2016-06-09 |
| JP2016534084A (ja) | 2016-11-04 |
| EP3060207A4 (en) | 2017-04-12 |
| US20170157089A1 (en) | 2017-06-08 |
| CA2927148A1 (en) | 2015-04-30 |
| MX2016004678A (es) | 2017-03-10 |
| JP6389884B2 (ja) | 2018-09-12 |
| CN105848654A (zh) | 2016-08-10 |
| CN105848654B (zh) | 2018-10-02 |
| KR20160065986A (ko) | 2016-06-09 |
| RU2016114498A3 (enExample) | 2018-08-13 |
| RU2016114498A (ru) | 2017-11-29 |
| WO2015061229A1 (en) | 2015-04-30 |
| US9511050B2 (en) | 2016-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| IL281058B1 (en) | Compositions and methods for treating anemia | |
| IL245281A0 (en) | Methods and preparations for the treatment of cancer | |
| SMT201700595T1 (it) | Composizioni e metodi per trattare il cancro | |
| SG10201801433XA (en) | Composition and vaccine for treating prostate cancer | |
| EP3077049A4 (en) | Compositions and methods for treating vitiligo | |
| IL239921A0 (en) | Preparations containing solutions in solid state and their use for the treatment of pain | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| SG11201508878WA (en) | Methods of treating cancer | |
| EP3004395A4 (en) | Compositions and methods for treating cancer | |
| EP3052102A4 (en) | Compositions and methods for treating cancers | |
| ZA201506330B (en) | Methods and compositions for treating leukemia | |
| SG11201510300RA (en) | Compositions and methods for treating skin | |
| PL3016682T3 (pl) | Sposoby leczenia nowotworu | |
| SG10201703977UA (en) | Methods of treating cancer | |
| EP2984185A4 (en) | Methods and compositions for treating cancer | |
| WO2014160368A9 (en) | Compositions and methods for treating cancer | |
| EP2841102A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |